The National Pharmaceutical Council (NPC) recently released the results of its annual survey of stakeholder views on comparative effectiveness research (CER) and the environment for health care decision-making. Read more here. (Source: NPC, 2016) […]
ICER Releases Final Reports on Two New Diabetes and Asthma Drugs
The Institute for Clinical and Economic Review (ICER) recently released two final reports evaluating comparative clinical effectiveness and value of two new drugs. Learn more in the following reports: Mepolizumab for the Treatment of Severe Asthma with Eosinophilia: Effectiveness. Value. and […]
2015 Comparative Effectiveness Research Infographic
Now in its fifth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Infographic available for download here. (Source: National Pharmaceutical […]
The Myth of Average: Infographic for Patients
Understanding which health care treatments or preventive care will work best for you is important. This infographic for patients is available for download here. (Source: National Pharmaceutical Council) […]
The Myth of Average (Health Professionals) Infographic
Understanding which health care treatments or preventative care will work best for you is important. Infographic available for download here. (Source: National Pharmaceutical Council) […]
2014 Comparative Effectiveness Research and the Environment for Health Care Decision-Making Infographic
Now in its fourth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Take a look at this infographic. (Source: National Pharmaceutical Council) […]
New ICER Report to Review Obeticholic Acid
The Institute for Clinical and Economic Review (ICER) recently announced plans to develop a report assessing the comparative clinical effectiveness and value of obeticholic acid, a drug currently being considered for approval by the FDA for a rare liver condition. Read more here. (Source: ICER, […]
What Can the US Learn from the EU on Reimbursement and Pricing?
This case study takes a look at pharmaceutical reimbursement in the U.S. and the UK using Gilead's Hepatitis C drug, Sovaldi as an example of how the two different countries operate. What lessons can the U.S. learn from other countries like the UK on issues like value and pricing in the […]
ICER to Assess CER and Value of Diabetes Prevention Programs
The Institute for Clinical and Economic Review (ICER) recently announced plans to develop a report assessing the comparative effectiveness and value of diabetes prevention programs. Learn more here. (Source: ICER, 2/2/16) […]
Employer, Insurer, and Industry Perspectives on Patient-Centered CER
The Patient-Centered Outcomes Research Institute (PCORI) commissioned RAND and the National Pharmaceutical Council to conduct and independent study of the health-related decisions, information needs, understanding and use of CER. This report describes the key themes emerging from discussions RAND […]
What is Stopping Effective Comparative Drug Evaluation in the U.S.?
The only way to slow the inexorable rise of drug costs in the United States will require a level of comparative effectiveness research the industry has never seen, overcoming political and economic roadblocks. Read more here. (Source: Roger Longman, Journal of Clinical Pathways, 12/14/15) […]
ICER Releases Final Report on PCSK9 Use
The Institute for Clinical and Economic Review (ICER) recently posted the final report PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks, along with its accompanying Action Guides to the New England Comparative Effectiveness Public Advisory […]
ICER Report to Review Approaches to Palliative Care
The Institute for Clinical and Economic Review recently announced it will produce a report looking at the comparative effectiveness and value of palliative care delivered outside of the hospital setting. The report will be the subject of the New England Comparative Effectiveness Public Advisory […]
Which Drugs Will the ICER Review in 2016?
The Institute for Clinical and Economic Review (ICER) recently released an initial list of drugs it plans to review in 2016. Find out more about the ICER's new drug assessment program, which drugs will be reviewed, and how they were chosen, here. (Source: Mitchell Stein, ICER, 11/19/15) […]
eyeforpharma’s Evidence & Value Strategy Dossier
How can what payers need be aligned with the research developed? Are the findings from R&D what payers view as useful? Take a look at these industry case studies in the October edition of eyeforpharma's Evidence Value Strategy Dossier. More here. (Source: eyeforpharma, October 2015) […]
Don’t Miss Xcenda at ISPOR This Week
Join Xcenda's Global HEOR consultants in Milan, Italy as they demonstrate their global perspective, as well as findings from the latest evidence-based research at ISPOR's 18th Annual European Congress from November 7-11, 2015. Stop by and see the Xcenda team at booths #610, 611, 706, 707. View a […]
NPC Comments on ICER Value Assessment Framework
Robert Dubois, NPC Chief Science Officer, recently addressed the ICER Value Assessment Framework including 11 items he believes should be addressed. Read more here. (Source: Steven Pearson, National Pharmaceutical Council, 10/13/15) […]
What is Evidence from Clinical Experience and Why Does it Matter?
Panelist at a recent health care forum in Washington, DC raised concerns about the ability of the Food and Drug Administration (FDA) to effectively utilize evidence from clinical experience. Why is this type of evidence so important? What is it? How can it be used effectively in health care? Find […]
FREE Downloads!!! Online Calculators for HEOR: CEA, CUA, CBA, CMA
Health Decision Strategies, LLC (HDS), products and services has decision tools, questionnaires and software examples ready for you to try, including online calculators for HEOR: CEA, CUA, CBA, and CMA. Find out more here. (Source: HDS) […]
7 Point Checklist of Assessment for Research and Reimbursement
The key principles regarding what assessments lead to different types of guidance about the use of health technologies provide an explicit and transparent framework for technology appraisal. Read more here. (Source: Value in Health 18, 2015) […]
US Presidential Campaign Turns to Drug Pricing
The topic of pharmaceutical pricing has become a hot topic among US presidential candidates, however, whether just a political ploy or the beginning of a movement that will bring about real change has yet to be seen. The Center for American Progress recently issued a report driven by the desire to […]
How Do Payers View Comparative Effectiveness and Relative Effectiveness Research?
A recently published paper in the International Journal of Technology Assessment in Health Care examined the views of payers in the United States and Europe on the rapidly evolving fields of comparative effectiveness and relative effectiveness research. See more here. (Source: OHE, 8/18/15) […]
Online Resources for Comparative Effectiveness Research Programs
The CER Collaborative was formed by AMCP, ISPOR, and NPC to provide greater uniformity and transparency in the evaluation and use of evidence for coverage and health care decision-making with the ultimate goal of improving patients outcomes. The University of Maryland School of Pharmacy joins the […]
How Does the NPC View Drug Pricing Value Assessment Methods in the U.S.?
National Pharmaceutical Council's Chief Science Officer and Executive Vice President, Dr. Robert Dubois, recently sat down with Dr. Patti Peeples of HealthEconomics.Com to discuss Drug Value Frameworks, ETAP, and NPC's research agenda for comparative effectiveness. Here the NPC's viewpoint on drug […]
Pharm Exec’s Q&A with Pharmacoepidemiology Experts
Pharm Exec recently brought a group of pharmacoepidemiology experts together to discuss the complex task of measuring value. See the Q&A here. (Source: William Looney, Pharmaceutical Executive, 8/6/15) […]
CER Collaborative – Tools to Be Better at What You Do
To address the need for real-world understanding and use of the new research being generated, the Comparative Effectiveness Research (CER) Collaborative, a partnership among the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes Research, and the […]
Is Comparative Effectiveness Research Still Important?
According to new research from Cutting Edge Information, Comparative Effectiveness Research (CER) is more important than ever in an increasingly crowded marketplace and strained healthcare system. Learn more here. (Source: Market Watch, 7/29/15) […]
Good, Bad, or Indifferent on Drug Pricing
A value benchmark approach for newly launched drugs in the United States. Dr. Patti Peeples of HealthEconomics.Com recently interviewed Dr. Steve Pearson and Dr. Dan Ollendorf of ICER, to explore the goals behind (ETAP) and the implications for this new benchmark approach to drug pricing. See more […]
New Research Finds 44% of Surveyed Companies use HOLs to Deliver CER to Payers
New research from Cutting Edge Information shows that health outcomes liaisons (HOLs) are playing a large role in sharing comparative effectiveness research (CER) with payers. Learn more here. (Source: Market Watch, 7/22/15) […]
CER Collaborative Now Offering Flexible Option to Continuing Education
The Comparative Effectiveness Research (CER) Collaborative will be offering new flexible options for people interested in its 19-hour continuing education program. More details available here. (Source: National Pharmaceutical Council, 5/13/15) […]
